Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056553260> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2056553260 endingPage "804" @default.
- W2056553260 startingPage "800" @default.
- W2056553260 abstract "As a result of the low oral bioavailability of ganciclovir, a prodrug was developed to improve the bioavailability of ganciclovir. This study was designed to investigate the fasting, single-dose pharmacokinetics as well as the absolute and relative bioavailability of a valine ester prodrug of ganciclovir, valganciclovir, as compared to oral and intravenous ganciclovir in asymptomatic HIV+ and CMV+ subjects. In this open-label, randomized, three-period crossover study, 18 subjects received, in random order, single oral doses of valganciclovir 360 mg and ganciclovir 1000 mg and an intravenous infusion of ganciclovir 5 mg/kg over 1 hour. Valganciclovir was rapidly and extensively hydrolyzed to ganciclovir, resulting in significantly greater bioavailability compared to 1000 mg oral ganciclovir (60.9% vs. 5.6%, respectively). Higher peak serum concentrations were reached earlier following valganciclovir (ganciclovir [2.98 +/- 0.77 micrograms/mL at 1.0 +/- 0.3 h]) than following oral ganciclovir (0.47 +/- 0.17 microgram/mL and 2.2 +/- 1.0 h). Mean total ganciclovir AUCs following oral ganciclovir (1000 mg) and 360 mg valganciclovir (3.8 +/- 1.2 and 10.8 +/- 1.9 micrograms-h/mL) were less than that following a standard 5 mg/kg intravenous infusion of ganciclovir (25.1 +/- 3.8 micrograms-h/mL). In summary, valganciclovir is a prodrug with a favorable safety profile with enhanced bioavailability and significantly higher serum concentrations of ganciclovir than following oral administration of ganciclovir itself." @default.
- W2056553260 created "2016-06-24" @default.
- W2056553260 creator A5016359240 @default.
- W2056553260 creator A5084905695 @default.
- W2056553260 date "1999-08-01" @default.
- W2056553260 modified "2023-09-24" @default.
- W2056553260 title "Single-Dose Pharmacokinetics of Valganciclovir in HIV- and CMV-Seropositive Subjects" @default.
- W2056553260 cites W1965620086 @default.
- W2056553260 cites W1999725769 @default.
- W2056553260 cites W2011729503 @default.
- W2056553260 cites W2126065694 @default.
- W2056553260 cites W2334092403 @default.
- W2056553260 doi "https://doi.org/10.1177/00912709922008452" @default.
- W2056553260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10434231" @default.
- W2056553260 hasPublicationYear "1999" @default.
- W2056553260 type Work @default.
- W2056553260 sameAs 2056553260 @default.
- W2056553260 citedByCount "153" @default.
- W2056553260 countsByYear W20565532602012 @default.
- W2056553260 countsByYear W20565532602013 @default.
- W2056553260 countsByYear W20565532602014 @default.
- W2056553260 countsByYear W20565532602015 @default.
- W2056553260 countsByYear W20565532602016 @default.
- W2056553260 countsByYear W20565532602017 @default.
- W2056553260 countsByYear W20565532602018 @default.
- W2056553260 countsByYear W20565532602019 @default.
- W2056553260 countsByYear W20565532602020 @default.
- W2056553260 countsByYear W20565532602021 @default.
- W2056553260 countsByYear W20565532602022 @default.
- W2056553260 countsByYear W20565532602023 @default.
- W2056553260 crossrefType "journal-article" @default.
- W2056553260 hasAuthorship W2056553260A5016359240 @default.
- W2056553260 hasAuthorship W2056553260A5084905695 @default.
- W2056553260 hasConcept C108215921 @default.
- W2056553260 hasConcept C112705442 @default.
- W2056553260 hasConcept C181389837 @default.
- W2056553260 hasConcept C203014093 @default.
- W2056553260 hasConcept C22979827 @default.
- W2056553260 hasConcept C2522874641 @default.
- W2056553260 hasConcept C2776317777 @default.
- W2056553260 hasConcept C2777056448 @default.
- W2056553260 hasConcept C2777965375 @default.
- W2056553260 hasConcept C2779820661 @default.
- W2056553260 hasConcept C71924100 @default.
- W2056553260 hasConcept C98274493 @default.
- W2056553260 hasConceptScore W2056553260C108215921 @default.
- W2056553260 hasConceptScore W2056553260C112705442 @default.
- W2056553260 hasConceptScore W2056553260C181389837 @default.
- W2056553260 hasConceptScore W2056553260C203014093 @default.
- W2056553260 hasConceptScore W2056553260C22979827 @default.
- W2056553260 hasConceptScore W2056553260C2522874641 @default.
- W2056553260 hasConceptScore W2056553260C2776317777 @default.
- W2056553260 hasConceptScore W2056553260C2777056448 @default.
- W2056553260 hasConceptScore W2056553260C2777965375 @default.
- W2056553260 hasConceptScore W2056553260C2779820661 @default.
- W2056553260 hasConceptScore W2056553260C71924100 @default.
- W2056553260 hasConceptScore W2056553260C98274493 @default.
- W2056553260 hasIssue "8" @default.
- W2056553260 hasLocation W20565532601 @default.
- W2056553260 hasLocation W20565532602 @default.
- W2056553260 hasOpenAccess W2056553260 @default.
- W2056553260 hasPrimaryLocation W20565532601 @default.
- W2056553260 hasRelatedWork W111038150 @default.
- W2056553260 hasRelatedWork W1796348015 @default.
- W2056553260 hasRelatedWork W1870547027 @default.
- W2056553260 hasRelatedWork W2032368516 @default.
- W2056553260 hasRelatedWork W2056553260 @default.
- W2056553260 hasRelatedWork W2069936009 @default.
- W2056553260 hasRelatedWork W2317627837 @default.
- W2056553260 hasRelatedWork W2359419803 @default.
- W2056553260 hasRelatedWork W2418409895 @default.
- W2056553260 hasRelatedWork W2587902810 @default.
- W2056553260 hasVolume "39" @default.
- W2056553260 isParatext "false" @default.
- W2056553260 isRetracted "false" @default.
- W2056553260 magId "2056553260" @default.
- W2056553260 workType "article" @default.